O. D. Bragina, S. M. Deyev, E. Yu. Garbukov, V. E. Goldberg, V. I. Chernov, V. M. Tolmachev
{"title":"替代支架类放射性药物[<sup>99m</sup>Tc]Tc- adapt6与[<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>- g3对her2阳性乳腺癌患者诊断效果的直接比较","authors":"O. D. Bragina, S. M. Deyev, E. Yu. Garbukov, V. E. Goldberg, V. I. Chernov, V. M. Tolmachev","doi":"10.20538/1682-0363-2023-3-6-13","DOIUrl":null,"url":null,"abstract":"Aim. To perform a direct comparison of the diagnostic efficacy of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 in HER2-positive breast cancer patients before the systemic treatment. Materials and methods. The study included 11 patients with HER2-positive breast cancer (T1–4N0–2M0–1) before the initiation of systemic treatment. All patients underwent a radionuclide examination with [ 99m Tc]TcADAPT6 and [ 99m Tc]Tc-(HE) -G3 with the interval of 3–4 days. Single-photon emission computed tomography (SPECT) /computed tomography (CT) was performed 2 and 4 hours after [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc(HE) 3 -G3 administration, respectively. Results. The analysis of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 distribution showed their high uptake in the kidneys and liver. Breast tumors were visualized in all cases. The average tumor uptake of [99mTc]Tc-ADAPT6 was 4.7 ± 2.1, which was significantly higher than in the [99mTc]Tc-(HE)3-G3 injection (3.5 ± 1.7) (p < 0.005, paired t-test). The tumor-to-background ratio (15.2 ± 7.4 and 19.6 ± 12.4, respectively) had no statistical differences in both cases (p > 0.05, paired t-test). Liver metastases were visualized in patients 1 and 5 and corresponded to the projection of metastases according to contrast-enhanced abdominal CT. The accumulation of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 in the projection of metastases in both cases was significantly higher compared to the primary tumor (1.3 and 1.7 times higher in patient 1; 2.2 and 3.5 times higher in patient 5, respectively). Conclusion. Both [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 demonstrated the diagnostic efficacy in visualizing a primary HER2-positive tumor in breast cancer patients. However, [99mTc]Tc-ADEPT6 had higher accumulation values, which makes it a more promising diagnostic agent.","PeriodicalId":43691,"journal":{"name":"Byulleten Sibirskoy Meditsiny","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer\",\"authors\":\"O. D. Bragina, S. M. Deyev, E. Yu. Garbukov, V. E. Goldberg, V. I. Chernov, V. M. Tolmachev\",\"doi\":\"10.20538/1682-0363-2023-3-6-13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim. To perform a direct comparison of the diagnostic efficacy of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 in HER2-positive breast cancer patients before the systemic treatment. Materials and methods. The study included 11 patients with HER2-positive breast cancer (T1–4N0–2M0–1) before the initiation of systemic treatment. All patients underwent a radionuclide examination with [ 99m Tc]TcADAPT6 and [ 99m Tc]Tc-(HE) -G3 with the interval of 3–4 days. Single-photon emission computed tomography (SPECT) /computed tomography (CT) was performed 2 and 4 hours after [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc(HE) 3 -G3 administration, respectively. Results. The analysis of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 distribution showed their high uptake in the kidneys and liver. Breast tumors were visualized in all cases. The average tumor uptake of [99mTc]Tc-ADAPT6 was 4.7 ± 2.1, which was significantly higher than in the [99mTc]Tc-(HE)3-G3 injection (3.5 ± 1.7) (p < 0.005, paired t-test). The tumor-to-background ratio (15.2 ± 7.4 and 19.6 ± 12.4, respectively) had no statistical differences in both cases (p > 0.05, paired t-test). Liver metastases were visualized in patients 1 and 5 and corresponded to the projection of metastases according to contrast-enhanced abdominal CT. The accumulation of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 in the projection of metastases in both cases was significantly higher compared to the primary tumor (1.3 and 1.7 times higher in patient 1; 2.2 and 3.5 times higher in patient 5, respectively). Conclusion. Both [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 demonstrated the diagnostic efficacy in visualizing a primary HER2-positive tumor in breast cancer patients. However, [99mTc]Tc-ADEPT6 had higher accumulation values, which makes it a more promising diagnostic agent.\",\"PeriodicalId\":43691,\"journal\":{\"name\":\"Byulleten Sibirskoy Meditsiny\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Byulleten Sibirskoy Meditsiny\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20538/1682-0363-2023-3-6-13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Byulleten Sibirskoy Meditsiny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20538/1682-0363-2023-3-6-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer
Aim. To perform a direct comparison of the diagnostic efficacy of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 in HER2-positive breast cancer patients before the systemic treatment. Materials and methods. The study included 11 patients with HER2-positive breast cancer (T1–4N0–2M0–1) before the initiation of systemic treatment. All patients underwent a radionuclide examination with [ 99m Tc]TcADAPT6 and [ 99m Tc]Tc-(HE) -G3 with the interval of 3–4 days. Single-photon emission computed tomography (SPECT) /computed tomography (CT) was performed 2 and 4 hours after [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc(HE) 3 -G3 administration, respectively. Results. The analysis of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE) -G3 distribution showed their high uptake in the kidneys and liver. Breast tumors were visualized in all cases. The average tumor uptake of [99mTc]Tc-ADAPT6 was 4.7 ± 2.1, which was significantly higher than in the [99mTc]Tc-(HE)3-G3 injection (3.5 ± 1.7) (p < 0.005, paired t-test). The tumor-to-background ratio (15.2 ± 7.4 and 19.6 ± 12.4, respectively) had no statistical differences in both cases (p > 0.05, paired t-test). Liver metastases were visualized in patients 1 and 5 and corresponded to the projection of metastases according to contrast-enhanced abdominal CT. The accumulation of [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 in the projection of metastases in both cases was significantly higher compared to the primary tumor (1.3 and 1.7 times higher in patient 1; 2.2 and 3.5 times higher in patient 5, respectively). Conclusion. Both [ 99m Tc]Tc-ADAPT6 and [ 99m Tc]Tc-(HE)3-G3 demonstrated the diagnostic efficacy in visualizing a primary HER2-positive tumor in breast cancer patients. However, [99mTc]Tc-ADEPT6 had higher accumulation values, which makes it a more promising diagnostic agent.